Carl Dambkowski Sells 3,860 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total transaction of $139,809.20. Following the sale, the insider now directly owns 247,173 shares in the company, valued at approximately $8,952,606.06. This trade represents a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $32.32 on Friday. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $63.50. The stock has a market cap of $1.46 billion, a P/E ratio of -13.36 and a beta of 1.72. The firm’s fifty day moving average price is $37.21 and its 200-day moving average price is $45.45.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). Sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APGE. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 35.7% in the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock worth $282,798,000 after buying an additional 1,267,451 shares during the last quarter. Driehaus Capital Management LLC increased its stake in Apogee Therapeutics by 2.8% in the fourth quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock valued at $118,021,000 after acquiring an additional 71,703 shares during the last quarter. Alliancebernstein L.P. raised its position in Apogee Therapeutics by 13.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock valued at $61,390,000 after purchasing an additional 160,822 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in Apogee Therapeutics by 82.9% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company’s stock worth $58,155,000 after purchasing an additional 581,949 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Apogee Therapeutics by 141.7% during the fourth quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company’s stock worth $51,455,000 after purchasing an additional 665,543 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Wedbush reissued an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Citigroup began coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $95.00 price target for the company. Finally, Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Buy” and an average target price of $92.17.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.